353 related articles for article (PubMed ID: 31222604)
1. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
[TBL] [Abstract][Full Text] [Related]
2. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
3. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
[TBL] [Abstract][Full Text] [Related]
5. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
6. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Elkouzi A; Ramirez-Zamora A; Zeilman P; Barabas M; Eisinger RS; Malaty IA; Okun MS; Almeida L
Ann Clin Transl Neurol; 2019 Oct; 6(10):1989-1995. PubMed ID: 31518070
[TBL] [Abstract][Full Text] [Related]
7. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
9. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Tessitore A; Marano P; Modugno N; Pontieri FE; Tambasco N; Canesi M; Latorre A; Lopiano L; Sensi M; Quatrale R; Solla P; Defazio G; Melzi G; Costanzo AM; Gualberti G; di Luzio Paparatti U; Antonini A
J Neurol; 2018 May; 265(5):1124-1137. PubMed ID: 29516169
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
[TBL] [Abstract][Full Text] [Related]
11. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Williams DR; Evans AH; Fung VSC; Hayes M; Iansek R; Kimber T; O'Sullivan JD; Sue CM
Intern Med J; 2017 Oct; 47(10):1107-1113. PubMed ID: 28195385
[TBL] [Abstract][Full Text] [Related]
12. [Selection of the optimal device-aided therapy in Parkinson's disease].
Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
14. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
Buhmann C; Hilker R; Lingor P; Schrader C; Schwarz J; Wolz M; Reichmann H
J Neural Transm (Vienna); 2017 Aug; 124(8):1005-1013. PubMed ID: 28229223
[TBL] [Abstract][Full Text] [Related]
15. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
16. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K; Odin P; Nyholm D
CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
[TBL] [Abstract][Full Text] [Related]
18. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
19. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W
J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
